Ocular Therapeutix
Ocular Therapeutix Inc is an American biopharmaceutical company focused on formulation and commercialization of bioresorbable therapies for ophthalmic diseases. The company utilizes its proprietary hydrogel platform to deliver sustained-release drugs, featuring its commercial product Dextenza for post-surgical ocular inflammation and allergic conjunctivitis. Revenue is generated from commercial sales of ophthalmic drug inserts to pharmaceutical wholesalers alongside research collaboration agreements. Core end markets encompass ophthalmology clinics, ambulatory surgical centers, and eye hospitals in the United States. Ocular Therapeutix holds an established position as an innovator in sustained-release hydrogel drug delivery for eye care. The company is headquartered in Bedford, Massachusetts, and its common stock trades on the Nasdaq Global Select Market.
5 of the funds FundTelligence covers report a position in Ocular Therapeutix.
- Legal name
- Ocular Therapeutix Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 5
- Exposure themes
- Ageing & Longevity, Healthy Ageing & Function, Vision
Funds holding Ocular Therapeutix
- Lannebo Global Growth — Lannebo · 1.56 % (full portfolio disclosed, June 2026)
- DNB Bioteknologi — DNB · 1.07 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.09 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)